Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rel-Cisapride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 15/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | RAD52 | P43351 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.98 |
| ▸ | USP2 | O75604 | 1/20 | 0.98 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.98 |
| ▸ | MLNR | O43193 | 1/20 | 0.98 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.98 |
| ▸ | HTR3B | O95264 | 1/20 | 0.98 |
| ▸ | HMGCR | P04035 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | DRD2 | P14416 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | DRD1 | P21728 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rel-Cisapride SCHEMBL9721799 | 1.00 | KCNH2 (1.00) | KCNH2MAPTRAD52ABCB11HTR4 | |
| Rel-Cisapride SCHEMBL220352 | 1.00 | KCNH2 (1.00) | KCNH2MAPTRAD52ABCB11HTR4 | |
| Cisapride SCHEMBL467063 | 1.00 | KCNH2 (1.00) | KCNH2MAPTRAD52ABCB11HTR4 | |
| Rel-Cisapride SCHEMBL29389140 | 0.99 | HTR4 (1.00) | KCNH2MAPTRAD52ABCB11HTR4 | |
| Cisapride SCHEMBL5053853 | 0.99 | HTR4 (1.00) | KCNH2MAPTRAD52ABCB11HTR4 | |
| Rel-Cisapride SCHEMBL16132 | 0.99 | HTR4 (1.00) | KCNH2MAPTRAD52ABCB11HTR4 | |
| Rel-Cisapride SCHEMBL1759279 | 0.99 | HTR4 (1.00) | KCNH2MAPTRAD52ABCB11HTR4 | |
| Rel-Cisapride SCHEMBL7854542 | 0.99 | HTR4 (1.00) | KCNH2MAPTRAD52ABCB11HTR4 | |
| Rel-Cisapride SCHEMBL16133 | 0.99 | HTR4 (1.00) | KCNH2MAPTRAD52ABCB11HTR4 | |
| Cisapride SCHEMBL16131 | 0.99 | HTR4 (1.00) | KCNH2MAPTRAD52ABCB11HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| US-20130123485-A1 | CATIONIC LIPIDS, METHODS FOR PREPARING THE SAME, AND DELIVERY SYSTEMS HAVING ABILITY TO TRANSITION INTO CELLS COMPRISING THE SAME | BIOPOLYMED INC. (KR) | 2013-05-16 | — | — | US | claimed |
| CN-102245171-A | Sustained-release microparticles and process for producing the same | AMOREPACIFIC CORP | 2011-11-16 | — | — | CN | claimed |
| US-20110217371-A1 | CONTROLLED-RELEASE MICROPARTICLES AND METHOD OF PREPARING SAME | AMOREPACIFIC CORPORATION (KR) | 2011-09-08 | — | — | US | claimed |
| JP-4722295-B2 | — | — | 2011-07-13 | — | — | JP | claimed |
| US-20110052723-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | claimed |
| WO-2010101649-A2 | SIGMA 1 RECEPTOR INHIBITION AS A NOVEL THERAPEUTICAL APPROACH AGAINST HEPATITIS C VIRUS INFECTION | GASTAMINZA PABLO (US) | 2010-09-10 | — | — | WO | claimed |
| EP-1159964-B1 | Use of growth hormone secretagogues for stimulating gastrointestinal motility | PFIZER PROD INC (US) | 2009-10-28 | — | — | EP | claimed |
| EP-2090311-A1 | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-08-19 | — | — | EP | claimed |
| US-20090181976-A1 | Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-07-16 | — | — | US | claimed |
| US-6548501-B2 | Composition and methods for stimulating gastrointestinal motility | PFIZER INC. | 2003-04-15 | — | — | US | claimed |
| US-20020142050-A1 | Porous drug matrices and methods of manufacture thereof | ACUSPHERE INC. | 2002-10-03 | — | — | US | claimed |
| CN-1365274-A | Porous drug matrices and methods of making same | ACUSPHERE INC (US) | 2002-08-21 | — | — | CN | claimed |
| US-20020042419-A1 | Composition and methods for stimulating gastrointestinal motility | RAQUALIA PHARMA INC. (JP) | 2002-04-11 | — | — | US | claimed |
| EP-1180020-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | Acusphere, Inc. (US) | 2002-02-20 | — | — | EP | claimed |
| EP-0910345-B1 | BICONVEX RAPIDLY DISINTEGRATING DOSAGE FORMS | JANSSEN PHARMACEUTICA NV (BE) | 2002-02-13 | — | — | EP | claimed |
| WO-2000072827-A9 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE INC (US) | 2002-01-31 | — | — | WO | claimed |
| EP-1159964-A2 | Compositions and methods for stimulating gastrointestinal motility | Pfizer Products Inc. (US) | 2001-12-05 | — | — | EP | claimed |
| US-6224905-B1 | POROUS MATRIX NETWORK | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-05-01 | — | — | US | claimed |
| WO-2000072827-A2 | POROUS DRUG MATRICES AND METHODS OF MANUFACTURE THEREOF | ACUSPHERE, INC. (US) | 2000-12-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123485-A1 | CATIONIC LIPIDS, METHODS FOR PREPARING THE SAME, AND DELIVERY SYSTEMS HAVING ABILITY TO TRANSITION INTO CELLS COMPRISING THE SAME | SGMS1, SGMS2, NPC1L1 | HTR4 4731/4885KCNH2 2055/4885MAPT 3085/4885 |
| US-20090181976-A1 | Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome | SIGMAR1, GPR119, TMEM97 | HTR4 29/4885KCNH2 2765/4885MAPT 3205/4885 |
| US-20020042419-A1 | Composition and methods for stimulating gastrointestinal motility | GHSR, GHRHR, GIPR | HTR4 946/4885KCNH2 1528/4885MAPT 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.